美国机器人胸腺肿瘤切除的国家趋势与围术期结局:倾向匹配与开放及胸腔镜比较
该研究基于美国国家癌症数据库2010—2014年2558例胸腺肿瘤切除患者,评估机器人胸腺切除的趋势与结局。机器人使用率从6%升至14%,开展医院从22家增至52家。倾向匹配后,机器人组在切缘阳性、淋巴结清扫、30天再入院及30/90天死亡率与开放或VATS无差异,5年总生存亦无差异。
要点
- 机器人胸腺切除使用率4年内从6%升至14%,开展医院数翻倍。
- 学术癌症项目、2014年诊断及亚洲人种与机器人使用独立相关。
- 匹配后机器人组与开放或VATS在切缘、再入院及死亡率无差异。
核心结论
- 4年间机器人胸腺切除使用显著增加,开展医院数增加。
- 匹配分析中机器人入路与VATS或开放入路围术期结局及5年总生存相当。
- 当前趋势显示机器人更多用于小胸腺瘤且围术期结果优良。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2010—2014年胸腺肿瘤切除患者。
- 共2558例胸腺切除,机器人300例、VATS 280例、开放1978例。
- 采用 logistic 回归分析机器人使用预测因素,并行1:1倾向匹配(卡钳0.05)比较机器人 vs 开放及机器人 vs VATS。
主要发现
- 机器人使用率从2010年6%升至2014年14%,开展至少1例机器人胸腺切除的医院从22家增至52家。
- 学术研究/综合癌症项目(OR 1.66,CI 1.22-2.27)、2014年诊断(OR 2.23,CI 1.31-3.80)及亚洲人种(OR 1.68,CI 1.05-2.69)为机器人使用的独立预测因素。
- 中西部医院(OR 0.65,CI 0.42-0.99)、较大肿瘤(cm)(OR 0.85,CI 0.80-0.90)、侵犯邻近器官(OR 0.55,CI 0.37-0.82)、胸腺癌(OR 0.62,CI 0.40-0.97)及诱导化疗后(OR 0.22,CI 0.08-0.61)较少使用机器人。
- 倾向匹配后,机器人组与开放或VATS组在切缘阳性、淋巴结清扫、30天再入院率及30/90天死亡率无差异。
- 机器人组较VATS组转换率更低,较开放组有住院时间缩短趋势;匹配组5年总生存无差异(机器人93% vs VATS 94%,P=0.571;机器人91% vs 开放80%,P=0.094)。
临床怎么用
- 对于小胸腺瘤,机器人胸腺切除可作为与VATS或开放手术相当的选项。
- 学术癌症项目及较近年份更倾向于采用机器人入路,但中西部医院使用较少。
- 较大肿瘤、侵犯邻近器官、胸腺癌或诱导化疗后患者较少选择机器人入路。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite the recent increased rate of adoption of robotic approaches for the resection of thymic tumours, their use is still limited to large-volume academic centres. To date, a large-scale analysis of the robotic approach has not been performed. We assessed the recent trends and outcomes of robotic thymectomies in the United States compared to those of open and video-assisted thoracoscopic surgical (VATS) approaches. METHODS: The National Cancer Database was queried for patients who underwent resection for thymic tumours (2010-2014). Predictors of using the robotic approach were estimated by logistic regression analysis. Propensity matching analysis (robotic versus open and robotic versus VATS) was done (1:1-caliper 0.05), controlling for age, gender, comorbidity index, induction treatment, tumour size and tumour extension. RESULTS: A total of 2558 thymectomies were performed (robotic = 300, VATS = 280, open = 1978). The use of a robotic approach increased from 6% (2010) to 14% (2014). The number of hospitals performing at least 1 robotic thymectomy increased from 22 (2010) to 52 (2014). Independent predictors influencing the choice of a robotic approach included an academic research/integrated cancer programme [odds ratio (OR) 1.66, confidence interval (CI) 1.22-2.27], later year of diagnosis (2014; OR 2.23, CI 1.31-3.80) and a patient's race (Asian) (OR 1.68, CI 1.05-2.69). A robotic approach was less likely to be utilized in midwestern hospitals (OR 0.65, CI 0.42-0.99), in larger tumours (cm) (OR 0.85, CI 0.80-0.90), with invasion of adjacent organs (OR 0.55, CI 0.37-0.82), thymic carcinoma (OR 0.62, CI 0.40-0.97) and following induction chemotherapy (OR 0.22, CI 0.08-0.61). In a propensity-matched analysis, there were no differences in the incidence of positive margins, nodal dissection, 30-day readmission rates and 30-/90-day mortality rates between the groups. However, a robotic approach was associated with fewer conversions compared to VATS, with a trend towards a shorter length of stay compared to an open approach. There were no differences in the 5-year overall survival rate between the matched groups (robotic 93% vs VATS 94%; P = 0.571; robotic 91% vs open 80%; P = 0.094). CONCLUSIONS: Over a 4-year study period, there was a significant increase in robotic utilization for thymectomies and an increase in the number of hospitals performing the procedure. In a matched analysis, a robotic approach was comparable to a VATS or an open approach. Current trends demonstrate increased robotic utilization for small thymomas with excellent perioperative results.
引用
- Kamel MK, Villena-Vargas J, Rahouma M, et al. National trends and perioperative outcomes of robotic resection of thymic tumours in the United States: a propensity matching comparison with open and video-assisted thoracoscopic approaches†. Eur J Cardiothorac Surg. 2019. PMID: 31321412. doi:10.1093/ejcts/ezz111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。